Radiomics to predict immunotherapy-induced pneumonitis: proof of concept

被引:0
作者
Rivka R. Colen
Takeo Fujii
Mehmet Asim Bilen
Aikaterini Kotrotsou
Srishti Abrol
Kenneth R. Hess
Joud Hajjar
Maria E. Suarez-Almazor
Anas Alshawa
David S. Hong
Dunia Giniebra-Camejo
Bettzy Stephen
Vivek Subbiah
Ajay Sheshadri
Tito Mendoza
Siqing Fu
Padmanee Sharma
Funda Meric-Bernstam
Aung Naing
机构
[1] The University of Texas MD Anderson Cancer Center,Department of Diagnostic Radiology
[2] The University of Texas MD Anderson Cancer Center,Department of Cancer Systems Imaging
[3] The University of Texas MD Anderson Cancer Center,Department of Investigational Cancer Therapeutics
[4] The University of Texas MD Anderson Cancer Center,Department of Biostatistics
[5] Baylor College of Medicine,Department of Immunology, Allergy, and Rheumatology
[6] The University of Texas MD Anderson Cancer Center,Department of General Internal Medicine
[7] The University of Texas MD Anderson Cancer Center,Department of Pulmonary Medicine
[8] The University of Texas MD Anderson Cancer Center,Department of Symptom Research
[9] The University of Texas MD Anderson Cancer Center,Department of Genitourinary Medical Oncology
来源
Investigational New Drugs | 2018年 / 36卷
关键词
Immunotherapy; Immune-related adverse event; Pneumonitis; Radiomics;
D O I
暂无
中图分类号
学科分类号
摘要
We present the first reported work that explores the potential of radiomics to predict patients who are at risk for developing immunotherapy-induced pneumonitis. Despite promising results with immunotherapies, immune-related adverse events (irAEs) are challenging. Although less common, pneumonitis is a potentially fatal irAE. Thus, early detection is critical for improving treatment outcomes; an urgent need to identify biomarkers that predict patients at risk for pneumonitis exists. Radiomics, an emerging field, is the automated extraction of high fidelity, high-dimensional imaging features from standard medical images and allows for comprehensive visualization and characterization of the tissue of interest and corresponding microenvironment. In this pilot study, we sought to determine whether radiomics has the potential to predict development of pneumonitis. We performed radiomic analyses using baseline chest computed tomography images of patients who did (N = 2) and did not (N = 30) develop immunotherapy-induced pneumonitis. We extracted 1860 radiomic features in each patient. Maximum relevance and minimum redundancy feature selection method, anomaly detection algorithm, and leave-one-out cross-validation identified radiomic features that were significantly different and predicted subsequent immunotherapy-induced pneumonitis (accuracy, 100% [p = 0.0033]). This study suggests that radiomic features can classify and predict those patients at baseline who will subsequently develop immunotherapy-induced pneumonitis, further enabling risk-stratification that will ultimately lead to better treatment outcomes.
引用
收藏
页码:601 / 607
页数:6
相关论文
共 203 条
[1]  
Dizon DS(2016)Clinical cancer advances 2016: annual report on progress against cancer from the American Society of Clinical Oncology J Clin Oncol 34 987-1011
[2]  
Krilov L(2015)Toxicities of immunotherapy for the practitioner J Clin Oncol 33 2092-2099
[3]  
Cohen E(2014)Survival, durable tumor remission, and long-term safety in patients with advanced melanoma receiving nivolumab J Clin Oncol 32 1020-1030
[4]  
Gangadhar T(2012)Safety, activity, and immune correlates of anti-PD-1 antibody in cancer N Engl J Med 366 2443-2454
[5]  
Ganz PA(2014)Mitigating the toxic effects of anticancer immunotherapy Nat Rev Clin Oncol 11 91-99
[6]  
Hensing TA(2015)Overall survival and long-term safety of nivolumab (anti-programmed death 1 antibody, BMS-936558, ONO-4538) in patients with previously treated advanced non-small-cell lung cancer J Clin Oncol 33 2004-U2032
[7]  
Hunger S(2015)Pembrolizumab for the treatment of non-small-cell lung cancer N Engl J Med 372 2018-2028
[8]  
Krishnamurthi SS(2015)Nivolumab and ipilimumab versus ipilimumab in untreated melanoma N Engl J Med 372 2006-2017
[9]  
Lassman AB(2015)Anti-PD-1-related pneumonitis during cancer immunotherapy N Engl J Med 373 288-290
[10]  
Markham MJ(2015)Lung texture in serial thoracic computed tomography scans: correlation of radiomics-based features with radiation therapy dose and radiation pneumonitis development Int J Radiat Oncol Biol Phys 91 1048-1056